Consensus ChampionX Corporation

Equities

CHX

US15872M1045

Market Closed - Nasdaq 04:00:00 2024-06-12 pm EDT 5-day change 1st Jan Change
31.65 USD -0.25% Intraday chart for ChampionX Corporation +3.03% +8.35%

Evolution of the average Target Price on ChampionX Corporation

Price target over the last 5 years

History of analyst recommendation changes

c1e6e9319556c71c0ee2566106eb8a6.vrIcG2yM8-DTEY82To_eQN620dmYJ33tNNTjqJ2MNwo.y8Urayniia2ja7dOBL2tFJbSsOnaUxCPeeKv-MjJWTPYgUNLON65s7Bo2g~295511963f8684e04bf7a43bcb65a479
Piper Sandler Raises ChampionX's Price Target to $40 From $32, Maintains Neutral Rating MT
Barclays Raises Price Target on ChampionX to $51 From $39, Maintains Overweight Rating MT
RBC Raises Price Target on Schlumberger to $69 From $66 Amid ChampionX Deal, Keeps Outperform Rating MT
ChampionX Insider Sold Shares Worth $978,408, According to a Recent SEC Filing MT
Piper Sandler Downgrades ChampionX to Neutral From Overweight, Adjusts Price Target to $32 From $38 MT
Goldman Sachs Cuts Price Target on ChampionX to $32 From $37, Maintains Neutral Rating MT
Piper Sandler Adjusts Price Target on ChampionX to $38 From $42, Maintains Overweight Rating MT
Barclays Upgrades ChampionX to Overweight Equal-Weight, Raises Price Target to $44 From $33 MT
Capital One Initiates ChampionX With Overweight Rating, $40 Price Target MT
Citigroup Trims Price Target on ChampionX to $40 From $41, Maintains Buy Rating MT
Goldman Sachs Adjusts ChampionX's Price Target to $32 From $21, Keeps Neutral Rating MT
Citigroup Adjusts ChampionX Price Target to $34 From $30, Maintains Buy Rating MT
Barclays Downgrades ChampionX to Equalweight From Overweight, Reduces Price Target to $28 From $38 MT
ANALYST RECOMMENDATIONS : Nvidia, Thermo Fisher Scientific, Danaher, Agilent Technologies, GDS Holdings... Our Logo
Benchmark Starts ChampionX at Buy With $32 Price Target MT
BofA Securities Upgrades ChampionX to Buy From Neutral; Price Target is $22 MT
Goldman Sachs Lowers Price Target for ChampionX to $21 From $26, Maintains Neutral Rating MT
S&P Revises ChampionX Corp. Outlook To Positive On Improving Financial Measures, Ratings Affirmed MT
Barclays Adjusts ChampionX's Price Target to $38 from $33, Keeps Overweight Rating MT
Piper Sandler Lifts ChampionX to Overweight From Neutral, Price Target to $30 From $28 MT
BofA Securities Downgrades ChampionX to Neutral from Buy MT
Goldman Sachs Upgrades ChampionX to Neutral From Sell; Price Target is $24 MT
Barclays Adjusts Price Target on ChampionX to $35 From $29, Reiterates Overweight Rating MT
CHAMPIONX : Goldman Sachs Starts ChampionX at Sell With $22 Price Target MT
ANALYST RECOMMENDATIONS : Anthem, GlaxoSmithKline, Flutter, IMI, Workspace... Our Logo
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
31.73 USD
Average target price
41.89 USD
Spread / Average Target
+32.02%
High Price Target
51 USD
Spread / Highest target
+60.73%
Low Price Target
38 USD
Spread / Lowest Target
+19.76%

Consensus detail

Consensus revision (last 18 months)

Analysts covering ChampionX Corporation

Piper Sandler
Barclays
Goldman Sachs
Capital One Securities
Citigroup
Benchmark Company
BofA Securities
Stifel Nicolaus
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
  1. Stock Market
  2. Equities
  3. CHX Stock
  4. Consensus ChampionX Corporation